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Abstract
Introduction: There are an increasing number of reports of pregnancy in transplant recipients but many questions remain
regarding the effect of the transplant on pregnancy outcome, the pregnancy on the graft and the medication on the fetus.
The majority of studies reporting outcomes in transplant recipients have focused on women with kidney transplants, and
have included retrospective, voluntary registries or single centre studies.
Methods: The UK Obstetric Surveillance System (UKOSS) was used to prospectively identify all pregnant women with a liver
or cardiothoracic transplant in the United Kingdom, between January 2007 and January 2012. Data were collected on
demographics, transplant characteristics, immunosuppression regimens, antenatal care, maternal, graft and neonatal
outcomes. In an exploratory analysis, we tested for associations between ‘‘poor fetal outcome’’ and medications used before
or during pregnancy.
Results and conclusions: We report 62 pregnancies in 56 liver transplant recipients and 14 pregnancies in 14 cardiothoracic
transplant recipients (including 10 heart, three lung and one heart-lung recipient). Liver transplant recipients, in comparison
to cardiothoracic, had similar livebirth rates (92% vs. 87%) but better fetal outcomes (median gestational age 38 weeks vs.
35 weeks; median birthweight 2698 g vs. 2365 g), fewer caesarean deliveries (47% vs. 62%), fewer maternal intensive care
(ICU) admissions (19% vs. 29%) and fewer neonatal ICU admissions (25% vs. 54%). Nine women (12%) were taking
mycophenolate mofetil at conception, which was associated with adverse fetal outcomes. Pregnancy in transplant
recipients may have successful outcomes, but complication rates are high, emphasising the role of pre-conception
counselling and further research into the long-term effect on maternal and graft survival rates.
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Introduction
Over the past 50 years, more than 14,000 women with solid
organ transplants have had pregnancies, worldwide [1]. The
majority of studies on pregnancy outcomes in women with
transplants have included only women with renal transplants, with
information obtained from national, retrospective, voluntary
registries, with the only currently active registry being the National
Transplantation Pregnancy Registry (NTPR), in the United States
of America (USA) [2–4].
An international conference on reproduction and transplanta-
tion highlighted the need for prospective observational studies [5],
and recognised that many unanswered questions remain. For the
practicing clinician, further information is required regarding the
effect of the transplant on pregnancy, the effect of pregnancy on
the graft and the impact of medications on the fetus, particularly in
non-renal transplant recipients [6].
The aim of this study was to use the United Kingdom Obstetric
Surveillance System (UKOSS), which collects data on rare
disorders in pregnancy [7], to conduct a national, prospective
cohort study of pregnancy outcomes in liver and cardiothoracic
transplant recipients.
Methods
We aimed to identify all pregnant women in the United
Kingdom (UK), between January 2007 and January 2012, who
had previously undergone liver or cardiothoracic transplantation.
The UKOSS methodology has been described in detail
elsewhere [7]. In brief, nominated clinicians in each consultant-
led maternity unit in the UK were sent a case notification card
each month and asked to report all cases. They were also asked to
return cards indicating a ‘‘nil report’’ in order to distinguish no
cases of liver and cardiothoracic transplant recipients from a lack
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of response. Reporting clinicians were then asked to complete data
collection forms to provide information about cases (Figure 1).
We collected data on demographics, transplant characteristics,
immunosuppression regimens, antenatal care, and maternal, graft
and neonatal outcomes. All data collected were anonymous and
the entire cohort of women giving birth in the UK was included.
As the study spanned five years, year of birth, height and the organ
transplanted were used to identify successive pregnancies in the
same recipient.
Continuous variables were summarized as means (standard
deviations), or medians (inter-quartile or entire ranges) for skewed
data. Categorical variables were summarized as frequencies
(percentages).
Small-for-gestational age was calculated by comparing birth-
weight to revised British 1990 birth centiles [8], using LMSgrowth
software [9]. As data were not collected on the sex of infants born
to the transplant recipients, a best-case scenario was generated
assuming all infants were female and worst-case scenario assuming
all infants were male. Any infants below the 10th centile were
considered to be small-for-gestational age.
Poor fetal outcome was defined as any pregnancy resulting in a
stillbirth, miscarriage, very low birthweight (,1500 g), small-for-
gestational age (,10th centile, best-case scenario), congenital
anomaly, neonatal unit admission and very preterm birth (,32
weeks). This was used to generate a categorical variable which was
tested for association with medications used before or during
pregnancy. To allow for non-independence of multiple pregnan-
cies from the same women, logistic regression with cluster analysis
was used to generate odds ratios, p-values and 95% confidence
intervals.
All statistical analyses were carried out using STATA 11 SE
software (StataCorp LP, College Station, TX).
Ethics Statement
The UK Obstetric Surveillance System general methodology
(ref: 04/MRE02/45) and this study (ref: 06/MRE02/78) were
approved by the London Multicentre Research Ethics Committee.
Figure 1. Case reporting and completeness of data collection.
doi:10.1371/journal.pone.0089151.g001
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Results
All 228 hospitals in the UK with obstetrician-led maternity units
participated in the study (100% of eligible units), with data
collection from January 2007 until February 2012. Nineteen
hospitals ceased reporting cases during the study period, because
the admitting units had closed. Case ascertainment is presented in
Figure 1.
Patient Characteristics
We identified 62 pregnancies in 56 liver transplant recipients
and 14 pregnancies in 14 cardiothoracic transplant recipients,
including 10 heart, three lung and one heart-lung recipient.
The demographic, maternal and transplant characteristics of
the population are presented in Table 1.
Women with a liver transplant had a median age of 30 years at
pregnancy (range 18–39 years), median age of 21 years at first
transplantation (range 2–36 years, 34% below age 18) and a
median transplant to conception interval of 6.5 years (range 4
months to 20 years). Seven women conceived within two years of
liver transplantation, with two occurring within the first year. The
most common indications for transplantation (Table 2) were acute
liver failure (secondary to drug toxicity), biliary atresia, metabolic
diseases, seronegative and autoimmune hepatitides.
Women with a cardiothoracic transplant had a median age of
26 at delivery (range 20–38 years), median age of 21 at first
transplantation (range 4–33 years, 43% below age 18) and a
median transplant to conception interval of 8 years (range 2–16
years), reflecting the burden of congenital disease, with almost half
(n = 6) transplanted for congenital heart disease and cystic fibrosis
(Table 2). No women conceived within two years of receiving a
cardiothoracic transplant.
Management
Of the 76 transplant recipients, 45 received antenatal care in the
usual hospital for their area of residence (59%). Of those who
received care at another hospital, 28 (37%) were referred because
of their underlying medical condition.
Table 1. Demographic, maternal and transplant characteristics of liver and cardiothoracic transplant recipients.
Demographic Characteristics Liver transplant cohort (n =62) Cardiothoracic transplant cohort (n=14)
Maternal age (years)
,20 3 (5) 0 (0)
20–34 45 (73) 11 (79)
$35 14 (23) 3 (21)
Ethnic group1
White 44 (80) 12 (92)
Non-White 11 (20) 1 (8)
Socio-economic status
Managerial/Professional 17 (33) 2 (15)
Non-managerial/Other 26 (51) 6 (46)
Unemployed 8 (16) 5 (38)
Smoking status
Smoked during pregnancy 16 (27) 3 (21)
Did not smoke during pregnancy 43 (73) 11 (79)
Body mass index
Normal (,25) 34 (57) 11 (79)
Overweight (25–29) 18 (30) 1 (7)
Obese ($30) 8 (13) 2 (14)
Multiple pregnancy
No 62 (100) 13 (93)
Yes 0 (0) 1 (7)
Parity
0 34 (55) 10 (71)
1 18 (29) 4 (29)
2+ 10 (16) 0 (0)
Transplant to conception interval
Less than 1 year 2 (3) 0 (0)
1–2 years 5 (8) 0 (0)
2–5 years 16 (26) 3 (21)
More than 5 years 39 (63) 11 (79)
Data are shown as n (%), with percentages referring to complete data only.
1Reported for 70 transplant women, rather than 76 pregnancies, as this characteristic will not have changed with repeated pregnancies.
doi:10.1371/journal.pone.0089151.t001
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Immunosuppressants and Medication during Pregnancy
Tacrolimus was the most commonly used immunosuppressant
in both groups of recipients (n = 58, 76%), followed by prednis-
olone (38%) and azathioprine (36%), as shown in Table 3. Nine
women were taking mycophenolate mofetil (MMF) at conception,
with three continuing MMF throughout the pregnancy (doses
ranging from 500 to 2000 mg per day); one woman took sirolimus
throughout her pregnancy.
Three women took ACE inhibitors or angiotensin receptor
blockers at conception and 11 women took aspirin at conception.
Fetal Outcomes
Fetal outcomes are reported in Table 4 and Table 5. There
were 70 live births (91% of all pregnancies), and the live birth
proportion was similar between the cardiothoracic and liver
Table 2. Indication for transplantation in liver transplant recipients (n = 56) and cardiothoracic transplant recipients (n = 14).
Category Indication Number (%)
Liver transplant recipients Acute liver failure 15 (27)
Paracetamol 7 (13)
Other (ecstasy, sulfasalazine, viral) 8 (14)
Biliary atresia 8 (14)
Cirrhosis 13 (23)
Seronegative/autoimmune hepatitis 11 (20)
Other (alcohol, amyloid) 2 (3)
Metabolic disease 13 (23)
Wilson’s disease 8 (14)
Other (tyrosinaemia, alpha-1 antitrypsin deficiency) 5 (9)
Other (Budd-Chiari syndrome, primary sclerosing cholangitis, cystic fibrosis, malignancy) 7 (13)
Cardiothoracic transplant recipients Bronchiectatic disease 3 (21)
Cystic fibrosis 2 (14)
Obliterative bronchiectasis 1 (7)
Cardiomyopathies 6 (43)
Viral 3 (21)
Dilated 2 (14)
Non-infective 1 (7)
Congenital heart disease and primary pulmonary hypertension 5 (36)
doi:10.1371/journal.pone.0089151.t002
Table 3. Medications taken before or during pregnancy.
Drugs Liver transplant cohort (n=62) Cardiothoracic transplant cohort (n =14)
Immunosuppressants
Azathioprine 20 (32) 7 (50)
Cyclosporine 12 (19) 5 (36)
Prednisolone 24 (39) 5 (36)
Mycophenolate mofetil 7 (11) 2 (14)
Tacrolimus 49 (79) 9 (64)
Sirolimus 1 (2) 0 (0)
Antihypertensives
ACE inhibitors and angiotensin receptor blockers 1 (2) 2 (14)
Calcium-channel blockers 4 (6) 1 (7)
Other antihypertensives 5 (8) 6 (43)
Other
Aspirin 8 (13) 3 (21)
Dyspepsia drugs e.g. omeprazole, ranitidine 10 (16) 2 (14)
Anticoagulants 3 (5) 1 (7)
Data are shown as n (%), with percentages referring to complete data only.
doi:10.1371/journal.pone.0089151.t003
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recipients. There were two stillbirths, five miscarriages/termina-
tions and no neonatal deaths.
The median gestational age for live births to women with liver
transplants was 38 weeks, compared to 35 in the cardiothoracic
cohort (42% vs. 54% born before 37 weeks’ gestation). The
median birthweight in the liver cohort was 2698 g (range 1115–
3995 g), with 37% classified as low birthweight (,2500 g),
compared to 2364 g (range 1480–3420 g) in the cardiothoracic
cohort and 54% classified as low birthweight.
Thirty percent of neonates were admitted to a neonatal unit,
with 54% (n= 7) of the cardiothoracic cohort compared with 25%
of the liver cohort (n = 14). Our ‘‘best-case scenario’’ estimated
only one small-for-gestational age infant in the cardiothoracic
cohort (8%), compared to 9 (16%) in the liver cohort; ‘‘worst-case
scenario’’ estimated three (23%) and 12 (21%), respectively.
In our exploratory analysis, MMF had a statistically significant
association with poor fetal outcomes (p = 0.04, data not shown),
with seven of nine women, who received it prior to or during
pregnancy, experiencing adverse outcomes (odds ratio 5.31, 95%
confidence interval 1.05–26.96, Table 6). No other immunosup-
pressant was associated with adverse fetal outcomes.
Women receiving aspirin appeared less likely to have a poor
fetal outcome (p = 0.02, data not shown), with an odds ratio (OR)
of 0.21 (95% confidence interval 0.05–0.78).
Sixty-three percent of women were breastfeeding their infants at
discharge (n = 44).
Maternal Outcomes and Complications
Maternal outcomes are presented in Table 7. One cardiac
transplant recipient was delivered at 30 weeks’ gestation for
Table 4. Birth outcomes for 77 fetuses born to liver and cardiothoracic transplant recipients1.
Birth outcome Entire cohort (n =77)
Livebirth2 70 (91)
Termination of pregnancy for deteriorating maternal condition 1 (1)
First or second trimester miscarriage 4 (5)
Stillbirth 2 (3)
1Data have been grouped for confidentiality purposes, due to small numbers.
2Includes 57 livebirths to women with liver transplants and 13 livebirths to women with cardiothoracic transplants.
doi:10.1371/journal.pone.0089151.t004
Table 5. Fetal outcomes1 in liver (n = 57) and cardiothoracic transplant recipients (n = 13)*.
Liver transplant cohort n (%) Cardiothoracic transplant cohort n (%)
Apgar score at 5 minutes
More than 7 56 (98) 11 (85)
Less than 7 1 (2) 2 (15)
Gestational age at delivery
Less than 32 weeks 0 (0) 2 (15)
32–37 weeks 24 (42) 5 (38)
More than 37 weeks 33 (58) 6 (46)
Birthweight
1000–1499 g 1 (2) 1 (8)
1500–1999 g 6 (11) 3 (23)
2000–2499 g 14 (25) 3 (23)
More than 2500 g 36 (63) 6 (46)
Small-for-gestational age
Best-case scenario 9 (16) 1 (8)
Worst case scenario 12 (21) 3 (23)
Congenital anomaly 0 (0) 0 (0)
Neonatal unit admission 14 (25) 7 (54)
Infant breastfed
Yes 36 (63) 8 (62)
No 13 (23) 2 (15)
Not known 8 (14) 3 (23)
Data are shown as n (%), with percentages referring to complete data only.
1Denominator includes all live births,
*including one multiple pregnancy in cardiothoracic cohort.
doi:10.1371/journal.pone.0089151.t005
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deteriorating graft function, was admitted to intensive care and
died 12 days later, with post-mortem biopsy confirming acute
rejection. Two other women (one liver recipient, one cardiotho-
racic recipient) were reported to have an episode of rejection,
neither underwent biopsy.
Sixteen transplant recipients (21% of total; 12 liver recipients,
19%, four cardiothoracic recipients, 29%) were admitted to an
intensive care (ITU) or high dependency unit (HDU), though this
tended to be for a short duration (median 2 days, range 1–12
days).
Half of the cohort (n = 35) underwent caesarean section, with
the majority classed as Grade 3–4 (59%, n= 20) urgency, where
there was no immediate maternal or fetal compromise.
The most common indications for emergency caesarean
delivery (urgency grade 1–2, 41%, n= 14) were fetal compromise
(n = 9), including reduced fetal movements, cardiotocography
abnormality and cord prolapse, and maternal compromise (n = 5),
including pre-eclampsia and deteriorating graft function. Four
women underwent non-emergency caesarean section solely due to
their transplant or transplant surgery and two were at maternal
request.
Ten women (13%) were diagnosed with pre-eclampsia during
pregnancy and the percentage was similar between liver and
cardiothoracic recipients. Six women were diagnosed with
gestational diabetes, all of whom were on tacrolimus therapy
throughout their pregnancy; four of the six women were also
taking prednisolone.
Seventeen women (22%) were reported to have renal dysfunc-
tion during pregnancy with a 30% increase in serum creatinine
and seven women (9%) had serum creatinine greater than
150 umol/l during the third trimester.
Cardiothoracic transplant recipients had higher creatinine levels
during pregnancy than liver transplant recipients, with mean
serum creatinine of 104 during first trimester (vs. 77), and greater
increases by the third trimester (see Figure 2). Creatinine did not
decrease in the second trimester for liver transplant recipients.
Ten women (16%) in the liver transplant group had a diastolic
blood pressure greater than 100 mmHg, whilst seven (11%) had a
systolic blood pressure greater than 160 mmHg. Three women
(21%) in the cardiothoracic group had a diastolic blood pressure of
more than 100 mmHg, though none had a systolic blood pressure
greater than 160 mmHg.
Discussion
This study reports national, prospectively-collected pregnancy
outcome data for UK liver and cardiothoracic transplant
recipients, over a five year period. Similar to other studies
[1,10–12], we have found that the majority of pregnancies are
successful in transplant recipients, but with a high rate of
complications.
Liver transplant recipients, in comparison to cardiothoracic and
renal transplant recipients from a separate UKOSS cohort [13],
had similar livebirth rates (92% vs. 87% vs. 91%, respectively) but
lower prematurity rates (42% vs. 54% vs. 52%), fewer low
birthweight babies (37% vs. 54% vs. 48%), lower caesarean
delivery rates (47% vs. 62% vs. 64%), similar maternal ICU
admissions (19% vs. 29% vs. 21%) and fewer neonatal ICU
admissions (25% vs. 54% vs. 38%). This same study found that a
comparison cohort, of women from the general maternity
Table 6. Association of fetal outcomes with medications taken before or during pregnancy, in liver and cardiothoracic transplant
recipients (n = 77)1.
Good fetal
outcome (n=43)
Poor fetal
outcome2 (n =34)
Total
(n =77)
Odds ratio
(95% confidence interval)
Immunosuppressants3
Azathioprine 16 (37) 12 (35) 28 (36) 0.92 (0.36–2.23)
Cyclosporine 10 (23) 8 (24) 18 (23) 1.02 (0.37–2.78)
Prednisolone 18 (42) 12 (35) 30 (39) 0.76 (0.30–1.94)
Mycophenolate mofetil 2 (5) 7 (21) 9 (12) 5.31 (1.05–27.0)
Tacrolimus 33 (77) 25 (74) 58 (75) 0.84 (0.31–2.30)
Sirolimus 0 (0) 1 (3) 1 (1) Insufficient data
Anti-hypertensives4
ACE inhibitors and ARBs 2 (5) 1 (3) 3 (4) 0.62 (0.05–7.27)
Calcium-channel blockers 4 (9) 1 (3) 5 (6) 0.30 (0.03–2.86)
Other 5 (12) 6 (18) 11 (14) 1.63 (0.45–5.91)
Other4
Aspirin 10 (23) 2 (6) 12 (16) 0.21 (0.05–0.78)
Dyspepsia drugs 7 (16) 5 (15) 12 (16) 0.89 (0.27–2.84)
Anticoagulants 3 (7) 2 (6) 5 (6) 0.83 (0.19–3.63)
Data are shown as n (%), with percentages referring to complete data only, except for the last column which gives odds ratios with 95% confidence intervals in
parentheses.
1Denominator refers to all pregnancies, including one multiple pregnancy, but with cluster analysis for 70 women as six women had repeated pregnancies.
2Poor fetal outcome was defined as any pregnancy resulting in a stillbirth, miscarriage, very low birthweight (,1500 g), small-for-gestational age (,10th centile, best-
case scenario), congenital anomaly, neonatal unit admission and very preterm birth (,32 weeks).
3Refers to medications taken before and/or during pregnancy.
4Refers to medications taken before pregnancy.
ACE =Angiotensin-converting enzyme inhibitor; ARB =Angiotensin II receptor antagonist.
doi:10.1371/journal.pone.0089151.t006
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population had higher livebirth rates (99%), lower prematurity
rates (8%), fewer low birthweight babies (8%) and lower caesarean
delivery rates (24%), further supporting the finding of a higher rate
of complications in transplant recipients [13]. Thus complication
rates in all transplant recipients are higher than in the general UK
population, though liver recipients appear to have better rates than
cardiothoracic and renal transplant recipients.
This is consistent with existing literature, in which more
complications have been found in renal than liver transplant
recipients, in both single-centre studies [14] and meta-analyses
[10]. However, few studies have compared cardiothoracic
transplant to other organ recipients [1,3] and no meta-analyses
exist.
Table 7. Maternal outcomes in liver and cardiothoracic transplant recipients.
Maternal outcomes Liver transplant cohort (n =62) Cardiothoracic cohort (n =14)
Maternal death 0 (0) 1 (7)
Critical care admission 12 (19) 4 (29)
Duration of stay:
1–2 days 8 (67) 3 (75)
More than 2 days 4 (33) 1 (25)
Episode of rejection 1 (2) 2 (14)
Caesarean section 27 (47) 8 (62)
Grade of urgency1:
Grade 1–2 12 (46) 2 (25)
Grade 3–4 14 (54) 6 (75)
Renal function during pregnancy
Highest serum creatinine .150 umol/l 5 (8) 4 (29)
Highest serum creatinine .125 umol/l 10 (16) 5 (36)
Highest serum creatinine .100 umol/l 20 (32) 11 (79)
More than 30% increase in serum creatinine 12 (19) 5 (36)
More than 20% increase in serum creatinine 21 (34) 9 (64)
Blood pressure during pregnancy
Highest systolic blood pressure .160 mmHg 7 (11) 0 (0)
Highest diastolic blood pressure .100 mmHg 10 (16) 3 (21)
Conditions during pregnancy
Pre-eclampsia 8 (13) 2 (14)
Gestational diabetes 4 (6) 2 (14)
Data are shown as n (%), with percentages referring to complete data only.
1Grade 1 involves an immediate threat to the life of the woman or fetus; Grade 2 involves maternal or fetal compromise which is not immediately life-threatening; Grade
3 involves a need for early delivery but no maternal or fetal compromise; Grade 4 requires delivery at a time to suit the woman and maternity team [36].
doi:10.1371/journal.pone.0089151.t007
Figure 2. Highest serum creatinine level during each trimester of pregnancy, for liver and cardiothoracic transplant recipients.
doi:10.1371/journal.pone.0089151.g002
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While our study suggests poorer prognosis in the cardiothoracic
group compared to our liver recipients, our cohort also had the
lowest mean gestational age (35.5 weeks) and lowest mean
birthweight (2441 g) when compared to the other cardiothoracic
recipients in the literature (range 36.4–38.3 weeks, range 2600–
2143 g) [6,15–17]. As a national, prospective study we would
expect our data to be less subject to selection bias and reporting
bias inherent in single-centre studies and voluntary registries.
Nonetheless, an important caveat to this finding is the compar-
atively small number of cases analysed, and no external source of
case ascertainment was identified for our study period, as the UK
Transplant Pregnancy Registry only covered 1994 to 2001.
In a national, retrospective study conducted in Sweden [18],
which considered obstetric complications before and after organ
transplantation, high rates were found in women who conceived in
the years before transplant, particularly in renal compared to liver
transplant recipients, suggesting the important role of pre-existing
disease in affecting outcomes, particularly chronic kidney disease
and hypertension [19]. These factors are likely to be applicable to
our cardiothoracic cohort due to the high prevalence of
moderately severe, pre-existing renal impairment, as evidenced
by high creatinine levels (Figure 2), and congenital disease in this
group of women (Table 2). Though our study found 21% (n= 3) of
cardiothoracic recipients had diastolic blood pressure over
100 mmHg, other studies of heart transplant recipients and lung
transplant recipients, specifically, have found rates of 39% and
52%, respectively [12], though it is not clear which thresholds for
blood pressure or definition of ‘‘hypertension’’ they have used.
Another factor to consider is the generally poorer prognosis of
cardiothoracic transplant recipients outside of pregnancy. National
statistics have shown one-year survival in UK females of
reproductive age (15–49 years), transplanted between 2005 and
2007 for kidney, heart, heart-lung, lung and liver was 98–100%,
85%, 71%, 79%, 93% respectively (unpublished data, NHS Blood
and Transplant). Five-year survival in UK females of reproductive
age, transplanted between 2005 and 2007 for kidney, heart, heart-
lung, lung and liver was 92–98%, 80%, 57%, 53% and 80%
respectively. Thus, one-year survival and five-year survival are
generally lowest in cardiothoracic transplant recipients, and worse
in liver than renal transplant recipients, which will be partly
related to chronic rejection in the form of bronchiolitis obliterans
syndrome [20] and cardiac allograft vasculopathy [21] limiting
graft and patient survival after lung or cardiac transplantation,
respectively, even in non-pregnant populations.
We cannot comment on whether the reasons women choose to
become pregnant vary between regions within the UK or
worldwide, and between transplant groups. It is possible that
those women who became pregnant represent a healthier cohort
than women who did not become pregnant, and this is a limitation
that may distort results when making comparisons between
groups.
Allograft Function and Rejection in Pregnancy
Our study reports rejection rates of 2% in liver recipients (n = 1)
and 14% in cardiothoracic recipients (n = 2). This was biopsy-
proven in one of the cardiothoracic recipients, who died as a result
of acute rejection. There were no other graft losses or biopsies
undertaken. The UKOSS study of renal transplant recipients
found 2% (n= 2) had rejection episodes [13].
Other studies have reported higher rates of rejection in liver
recipients. For example, in a UK-based study, Christopher et al.
[22] found 17% (n= 12) had rejection episodes during pregnancy,
with an additional two cases (3%) occurring post-partum. Nagy
et al. [23], in the USA, found 10.5% (n= 4) experienced rejection
during pregnancy and a further two (5%) post-partum. In both
studies, there were no graft losses or re-transplantations during
pregnancy. Both studies were single-centre studies, conducted in
transplant units. A survey-based study of female solid organ
transplant recipients in British Columbia, Canada, found that 21%
(n= 7) experienced a rejection episode [24].
The National Transplantation Pregnancy Registry (NTPR)
found rejection rates of 16% in lung transplant recipients (n = 5),
0% in 5 heart-lung transplant recipients and 11% in heart
transplant recipients (n = 11), with graft loss within 2 years of
pregnancy of 3%, 20% and 14%, respectively [12]. A case series of
cystic fibrosis lung transplant recipients found a particularly high
rate of rejection (40%, n= 4), with progressive graft dysfunction
resulting in death in all four women within 38 months of delivery
[25].
Of note, two recent case reports [26,27] document pregnancy-
related sensitisation to HLA antigens, leading to rejection and
graft failure in cardiac transplant recipients. One of the cases
required re-transplantation (five months post-partum) [26], whilst
the other died two years later [27]. These case reports highlight
that although cardiothoracic recipients are at increased risk of
graft loss and have lower survival rates, further research to explore
the role of anti-HLA antibodies is needed [6].
Medication at Conception and during Pregnancy
Evidence about the potential effects on pregnancy of the older
immunosuppressive drugs is well established [28], however, there
is less experience with some of the newer medications in
pregnancy. Our study adds to the growing body of evidence that
mycophenolate mofetil can lead to adverse fetal outcomes
including congenital anomalies and a high probability of fetal loss
[29].
Congenital anomalies most commonly associated with ‘‘myco-
phenolate embryopathy’’ include microtia and orofacial cleft
defects [30], though there remain questions regarding the role of
complex immunosuppressant regimens and interactions. None of
these specific anomalies were reported in our cohort.
Of note, one of two patients to receive mycophenolate, with no
adverse fetal outcome, was treated with anticoagulants and anti-
platelet agents throughout pregnancy. The group receiving aspirin
at conception had a statistically significant lower likelihood of
adverse fetal outcomes, which is consistent with a recent meta-
analysis considering perinatal death, growth restriction and
preterm birth [31].
Only one patient in our study had exposure to sirolimus; she
had a poor pregnancy outcome. Though there have been reports
of successful pregnancies with sirolimus (16 of 23 pregnancies
resulted in livebirths in one report [12]), uncertainty remains
regarding potential teratogenic effects [32]. Interestingly, an
earlier report from the NTPR found no livebirths in women
who had continued on sirolimus throughout pregnancy, but
successful fetal outcomes in those discontinuing during pregnancy
[33]. It is important to note that most transplant recipients were
receiving more than one medication and this may affect
interpretation of the role of each medication in contributing to
outcomes; a caveat in nearly all obvservational studies of
pregnancy in women with complex diseases.
While the majority (60%) of our cohort breastfed their infants
and current international consensus suggests it should not be
viewed as absolutely contraindicated [5], the topic remains
controversial and many centres advocate avoidance to their
patients [15,17]. Recent evidence suggests that tacrolimus therapy
should not be a contraindication to breast feeding [34,35]. The
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role of registries, such as the NTPR, will be integral in long-term
follow-up of offspring for any adverse events.
Conclusion
In common with most of the literature, our study found the
majority of pregnancies in liver and cardiothoracic transplant
recipients were successful, although there were high complication
rates. Liver transplant recipients appear to have a better prognosis
than both renal and cardiothoracic recipients, which may be
related to them having a lower incidence of renal dysfunction,
hypertension, congenital diseases and graft loss. This study
confirmed the impact of renal dysfunction on pregnancy outcomes
and the need for ongoing monitoring throughout pregnancy. We
found an association between mycophenolate mofetil and poor
fetal outcomes. Given the risks of graft rejection on maternal
survival, this emphasises the role of pre-conception counselling in
addressing these risks. Further research will be needed to
investigate the long-term effects of pregnancy on maternal and
graft survival rates, for which surveillance systems and national
registries will prove invaluable.
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